Indivumed announces collaboration utilizing Aptila’s proteomics expertise

Indivumed is excited to collaborate with Aptila Biotech, a leader in DIA proteomics software.

Indivumed is pleased to announce a close working relationship with Aptila as of August 2025. Aptila’s software suite, DIA-NN, is a leading solution for data-independent acquisition (DIA) proteomics. This collaboration represents an additional advancement in Indivumed's novel target discovery approaches. By leveraging the innovative capabilities of DIA-NN, Indivumed aims to enhance the precision and effectiveness of their R&D, specifically in proteomics analysis.

Indivumed and Aptila join forces in a new proteomics collaboration. (Photo: Indivumed)

Indivumed's unique and standardized tissue collection process results in high quality multi-omics raw data, including proteomics and phospho-proteomics. When combined with longitudinal clinical data, this builds the basis for their patient-centric R&D approach.

With the DIA-NN software included in their comprehensive target discovery process, Indivumed can further optimize their data resource for deep proteomics analysis, providing unparalleled molecular insights that are critical for oncology therapeutic discovery.

This exciting opportunity combines both company’s strengths to make meaningful advancements in cancer research.

Source: Indivumed, 04.09.2025